Update (June 11, 2026): RCVS Knowledge Appraisal Rates Grapiprant Osteoarthritis Evidence as Weak

TL;DR

A 2026 RCVS Knowledge critically appraised topic rated the evidence that grapiprant reduces osteoarthritic pain in dogs as weak, finding it improves owner- and vet-assessed osteoarthritis outcomes but does not improve lameness in an acute, severe model.

What just dropped

Olding and Govendir published "Does grapiprant reduce osteoarthritic pain in dogs?" as a Knowledge Summary in Veterinary Evidence (14 April 2026; Vol. 11, No. 2; DOI 10.18849/ve.v11i2.732), the peer-reviewed evidence journal of RCVS Knowledge. The critically appraised topic synthesised the two randomized controlled trials that address the PICO question directly.

• Two randomized controlled trials were reviewed, and the overall strength of evidence was rated weak.
• One trial found that dogs with osteoarthritis given grapiprant had significant clinical improvement in both owner-assessed outcomes (treatment successes, pain interference scores, pain severity scores) and veterinarian-assessed outcomes (total orthopaedic scores) versus placebo.
• The second trial, in dogs with acute induced arthritis, found no significant differences in vertical force ratios or veterinarian-assessed visual lameness scores between grapiprant and control.
• The authors concluded grapiprant reduces the impact of osteoarthritic pain on activities of daily living and orthopaedic scores, but does not improve lameness associated with acute, severe osteoarthritic pain, and that further studies are needed.

Context

Grapiprant (Galliprant) is an EP4 prostaglandin-receptor antagonist of the piprant class, positioned as a targeted alternative to traditional COX-inhibiting NSAIDs for canine osteoarthritis pain. The appraisal's two pillars are familiar to the literature: the pivotal placebo-controlled field study supporting chronic-osteoarthritis efficacy, and an induced-arthritis comparison in which grapiprant underperformed. In that induced acute-arthritis study (de Salazar Alcala et al. 2019), firocoxib produced a high, sustained level of analgesia from the first post-treatment assessment, and its reduction in lameness was consistently superior to grapiprant, which was not significantly different from untreated controls.

The contrast matters clinically: grapiprant's evidence base is strongest for the chronic, owner-relevant burden of osteoarthritis rather than for rapid control of severe acute lameness, where a conventional coxib may act faster and more potently.

What this changes in the Grapiprant (Galliprant) evergreen

The grapiprant osteoarthritis page (https://www.thevoyage.ai/forvets/knowledge/grapiprant-canine-osteoarthritis-pain) summarises EP4 antagonism and the pivotal field-study evidence. This independent RCVS Knowledge appraisal adds a calibrated read on the strength of that evidence: it is rated weak and is inconsistent across models, with a clear benefit on chronic owner- and vet-assessed osteoarthritis outcomes but no demonstrated benefit on lameness in an acute, severe model where firocoxib was superior. For practice, this supports grapiprant as a reasonable option for the chronic-pain burden of osteoarthritis while tempering expectations for rapid relief of severe acute lameness, and it reinforces that head-to-head and larger trials are still needed.

References

1. Olding G, Govendir M. Does grapiprant reduce osteoarthritic pain in dogs? Veterinary Evidence. 2026;11(2). https://veterinaryevidence.org/index.php/ve/article/view/732
2. de Salazar Alcala AG, Gioda L, Dehman A, Beugnet F. Assessment of the efficacy of firocoxib (Previcox) and grapiprant (Galliprant) in an induced model of acute arthritis in dogs. BMC Veterinary Research. 2019;15:309. https://link.springer.com/article/10.1186/s12917-019-2052-0

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-11-grapiprant-evidence-strength-appraised

Changelog

• 2026-06-11: First published.

Related reads

• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile